Michael B. Maris

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Mohamed L. Sorror, Michael B. Maris, Rainer Storb et al. · Blood · 2005 · 2.9K citations · Full text

Medicine, Hematology, Risk Assessment +11

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

Marco Mielcarek, Paul J. Martin, Wendy M. Leisenring et al. · Blood · 2003 · 558 citations · Full text

Medicine, Hematology, Immunology +12

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning

Takahiro Fukuda, Michael Boeckh, Rachel A. Carter et al. · Blood · 2003 · 464 citations

Medicine, Hematology, Infectious Diseases +16

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases

Dietger Niederwieser, Michael B. Maris, Judith A. Shizuru et al. · Blood · 2003 · 455 citations · Full text

Medicine, Hematology, Immunology +17

Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation

Mohamed L. Sorror, Rainer Storb, Brenda M. Sandmaier et al. · Journal of Clinical Oncology · 2014 · 422 citations · Full text

Medicine, Hematology, Geriatric Assessment +13